Given the global burden of heart failure, strategies to understand the underlying cause or to
provide prognostic information are critical to reducing the morbidity and mortality associated …

Heart failure (HF), the leading cause of death in the western world, develops when a cardiac
injury or insult impairs the ability of the heart to pump blood and maintain tissue perfusion. It …

Heart failure is a syndrome characterized initially by left ventricular dysfunction that triggers
countermeasures aimed to restore cardiac output. These responses are compensatory at …

Beta‐blockers are widely used medications for a variety of indications, including heart
failure, myocardial infarction, cardiac arrhythmias, and hypertension. Genetic variability in …

Heterogeneity of heart failure (HF) phenotypes indicates contributions from underlying
common polymorphisms. We considered polymorphisms in the β1-adrenergic receptor …

The number of therapies for heart failure (HF) with reduced ejection fraction has nearly
doubled in the past decade. In addition, new therapies for HF caused by hypertrophic and …

At present, nine adrenoceptor (AR) subtypes have been identified: α1A-, α1B-, α1D-, α2A-,
α2B-, α2C-, β1-, β2-, and β3AR. In the human heart, β1-and β2AR are the most powerful …

a study of 491 Chinese patients treated with warfarin, the INR associated with the lowest
hemorrhagic and thromboembolic rate was 1.8 to 2.4. 10 These data suggest Asians may …

Cardiovascular diseases (CVDs) remain the leading cause of mortality worldwide and also
inflict major burdens on morbidity, quality of life, and societal costs. Considering that CVD …

The past decade has seen tremendous advances in our understanding of the genetic factors
influencing response to a variety of drugs, including those targeted at treatment of …